142 related articles for article (PubMed ID: 18413818)
1. Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention.
Hubner RA; Muir KR; Liu JF; Logan RF; Grainge MJ; Houlston RS;
Clin Cancer Res; 2008 Apr; 14(8):2303-9. PubMed ID: 18413818
[TBL] [Abstract][Full Text] [Related]
2. Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention.
Barry EL; Baron JA; Bhat S; Grau MV; Burke CA; Sandler RS; Ahnen DJ; Haile RW; O'Brien TG
J Natl Cancer Inst; 2006 Oct; 98(20):1494-500. PubMed ID: 17047198
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention.
Benamouzig R; Uzzan B; Martin A; Deyra J; Little J; Girard B; Chaussade S;
Gut; 2010 May; 59(5):622-9. PubMed ID: 20427397
[TBL] [Abstract][Full Text] [Related]
4. Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence.
Hubner RA; Muir KR; Liu JF; Logan RF; Grainge M; Armitage N; Shepherd V; Popat S; Houlston RS;
Clin Cancer Res; 2006 Nov; 12(21):6585-9. PubMed ID: 17085674
[TBL] [Abstract][Full Text] [Related]
5. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene.
Martinez ME; O'Brien TG; Fultz KE; Babbar N; Yerushalmi H; Qu N; Guo Y; Boorman D; Einspahr J; Alberts DS; Gerner EW
Proc Natl Acad Sci U S A; 2003 Jun; 100(13):7859-64. PubMed ID: 12810952
[TBL] [Abstract][Full Text] [Related]
6. Variants downstream of the ornithine decarboxylase gene influence risk of colorectal adenoma and aspirin chemoprevention.
Barry EL; Mott LA; Sandler RS; Ahnen DJ; Baron JA
Cancer Prev Res (Phila); 2011 Dec; 4(12):2072-82. PubMed ID: 21930798
[TBL] [Abstract][Full Text] [Related]
7. Ornithine decarboxylase G316A genotype and colorectal cancer risk.
Hughes DJ; Hlavatá I; Soucek P; Pardini B; Naccarati A; Vodickova L; O'Morain C; Vodicka P
Colorectal Dis; 2011 Aug; 13(8):860-4. PubMed ID: 20456464
[TBL] [Abstract][Full Text] [Related]
8. COX-2 expression in adenoma: an imperfect marker for chemoprevention.
Chan AT
Gut; 2010 May; 59(5):568-9. PubMed ID: 20427388
[No Abstract] [Full Text] [Related]
9. Dairy products, polymorphisms in the vitamin D receptor gene and colorectal adenoma recurrence.
Hubner RA; Muir KR; Liu JF; Logan RF; Grainge MJ; Houlston RS;
Int J Cancer; 2008 Aug; 123(3):586-93. PubMed ID: 18470879
[TBL] [Abstract][Full Text] [Related]
10. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk.
Bigler J; Whitton J; Lampe JW; Fosdick L; Bostick RM; Potter JD
Cancer Res; 2001 May; 61(9):3566-9. PubMed ID: 11325819
[TBL] [Abstract][Full Text] [Related]
11. Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival.
Zell JA; Ziogas A; Ignatenko N; Honda J; Qu N; Bobbs AS; Neuhausen SL; Gerner EW; Anton-Culver H
Clin Cancer Res; 2009 Oct; 15(19):6208-16. PubMed ID: 19789310
[TBL] [Abstract][Full Text] [Related]
12. Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients.
Zell JA; McLaren CE; Chen WP; Thompson PA; Gerner EW; Meyskens FL
J Natl Cancer Inst; 2010 Oct; 102(19):1513-6. PubMed ID: 20798393
[TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial.
Barry EL; Sansbury LB; Grau MV; Ali IU; Tsang S; Munroe DJ; Ahnen DJ; Sandler RS; Saibil F; Gui J; Bresalier RS; McKeown-Eyssen GE; Burke C; Baron JA
Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2726-33. PubMed ID: 19755647
[TBL] [Abstract][Full Text] [Related]
14. L-arginine reduces cell proliferation and ornithine decarboxylase activity in patients with colorectal adenoma and adenocarcinoma.
Ma Q; Wang Y; Gao X; Ma Z; Song Z
Clin Cancer Res; 2007 Dec; 13(24):7407-12. PubMed ID: 18094424
[TBL] [Abstract][Full Text] [Related]
15. Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?
Gill S; Sinicrope FA
Semin Oncol; 2005 Feb; 32(1):24-34. PubMed ID: 15726503
[TBL] [Abstract][Full Text] [Related]
16. MTHFR genotype and colorectal adenoma recurrence: data from a double-blind placebo-controlled clinical trial.
Levine AJ; Wallace K; Tsang S; Haile RW; Saibil F; Ahnen D; Cole BF; Barry EL; Munroe DJ; Ali IU; Ueland P; Baron JA
Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2409-15. PubMed ID: 18768511
[TBL] [Abstract][Full Text] [Related]
17. Genetic alterations of the ornithine decarboxylase gene in human colorectal cancers.
Matsubara N; Yoshitaka T; Hanafusa H; Tanaka N; Shimizu K
J Exp Clin Cancer Res; 2002 Jun; 21(2):191-5. PubMed ID: 12148577
[TBL] [Abstract][Full Text] [Related]
18. Folate metabolism polymorphisms influence risk of colorectal adenoma recurrence.
Hubner RA; Muir KR; Liu JF; Sellick GS; Logan RF; Grainge M; Armitage N; Chau I; Houlston RS
Cancer Epidemiol Biomarkers Prev; 2006 Sep; 15(9):1607-13. PubMed ID: 16985020
[TBL] [Abstract][Full Text] [Related]
19. DFMO: targeted risk reduction therapy for colorectal neoplasia.
Laukaitis CM; Gerner EW
Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):495-506. PubMed ID: 22122766
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.
Sandler RS; Halabi S; Baron JA; Budinger S; Paskett E; Keresztes R; Petrelli N; Pipas JM; Karp DD; Loprinzi CL; Steinbach G; Schilsky R
N Engl J Med; 2003 Mar; 348(10):883-90. PubMed ID: 12621132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
